Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 8/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29889978 | 1.00 | ERN1 (0.47) | ERN1PTPN1PTGDR2CYP2A6PRKDC | |
| SCHEMBL31550041 | 0.88 | ERN1 (0.52) | ERN1PTPN1PTGDR2CYP2A6PRKDC | |
| SCHEMBL1592418 | 0.82 | ERN1 (0.57) | ERN1PTPN1PTGDR2CYP2A6PRKDC | |
| SCHEMBL31088734 | 0.78 | ERN1 (0.44) | ERN1PTPN1PTGDR2CYP2A6PRKDC | |
| SCHEMBL16722745 | 0.78 | ERN1 (0.44) | ERN1PTPN1PTGDR2CYP2A6 | |
| SCHEMBL24268776 | 0.78 | ERN1 (0.44) | ERN1PTPN1PTGDR2CYP2A6PRKDC | |
| SCHEMBL1144801 | 0.78 | ERN1 (0.44) | ERN1PTPN1PTGDR2CYP2A6PRKDC | |
| SCHEMBL19792417 | 0.78 | ERN1 (0.44) | ERN1PTPN1PTGDR2CYP2A6PRKDC | |
| SCHEMBL24012721 | 0.78 | ERN1 (0.44) | ERN1PTPN1PTGDR2CYP2A6PRKDC | |
| SCHEMBL411126 | 0.78 | ERN1 (0.64) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698517-A1 | <SUP2/>? <SUB2/>?4?NOVEL COMPOUNDS AS ?? <NS1:SUB>7</NS1:SUB>?INHIBITORS | Evotec International GmbH (DE) | 2026-02-25 | — | — | EP | disclosed |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-10-07 | — | — | US | disclosed |
| US-20250171402-A1 | Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors | UNIV NORTHWESTERN (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4559525-A2 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | Morphic Therapeutic, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4045039-B1 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | MORPHIC THERAPEUTIC INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12240815-B2 | Potent and selective human neuronal nitric oxide synthase inhibitors | NORTHWESTERN UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4504709-A1 | CDK9 INHIBITORS | Biolexis Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240425479-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-12-26 | — | — | US | disclosed |
| WO-2024218058-A1 | NOVEL COMPOUNDS AS α4β7 INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024218059-A1 | NEW α4β7 INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2024-10-24 | — | — | WO | disclosed |
| WO-2012037410-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | ERN1 4701/4885PTPN1 3018/4885PTGDR2 134/4885 |
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | ERN1 1167/4885PTPN1 527/4885PTGDR2 1299/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | ERN1 975/4885PTPN1 621/4885PTGDR2 1477/4885 |
| US-12240815-B2 | Potent and selective human neuronal nitric oxide synthase inhibitors | NOS2, NOS1, NOS3 | ERN1 4607/4885PTPN1 2989/4885PTGDR2 223/4885 |
| US-20250171402-A1 | Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors | NOS2, NOS1, NOS3 | ERN1 4607/4885PTPN1 2989/4885PTGDR2 223/4885 |
| US-20240425479-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | DCK, CMPK1, WNK1 | ERN1 1245/4885PTPN1 596/4885PTGDR2 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.